Person:
Schleifer, Grigorij

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Schleifer

First Name

Grigorij

Name

Schleifer, Grigorij
Author's Publications: search.filters.isAuthorOfPublication.9d55fcda-933d-44a9-819e-3c4bd47ee557

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    An Engineered Enzyme That Targets Circulating Lactate to Alleviate Intracellular NADH:NAD+ Imbalance
    (Springer Science and Business Media LLC, 2020-01-13) Patgiri, Anupam; Skinner, Owen; Miyazaki, Yusuke; Schleifer, Grigorij; Marutani, Eizo; Shah, Hardik; Sharma, Rohit; Goodman, Russell; To, Tsz-Leung; Bao, Xiaoyan; Ichinose, Fumito; Zapol, Warren; Mootha, Vamsi
    An elevated intracellular NADH/NAD+ ratio, or “reductive stress,” has been associated with multiple diseases, including disorders of the mitochondrial electron transport chain (ETC). As the intracellular NADH/NAD+ ratio can be in near-equilibrium with the circulating lactate/pyruvate ratio, we hypothesized that reductive stress could be alleviated by oxidizing extracellular lactate into pyruvate. We engineered LOXCAT, a fusion of bacterial lactate oxidase (LOX) and catalase (CAT), which irreversibly converts lactate and oxygen to pyruvate and water. Addition of recombinant LOXCAT to the media of cultured human cells with a defective ETC was able to decrease the extracellular lactate/pyruvate ratio, normalize the intracellular NADH/NAD+ ratio, upregulate glycolytic ATP production, and restore cellular proliferation. In mice, tail-vein injected LOXCAT reduced circulating lactate/pyruvate ratio, blunted a metformin-induced rise in blood lactate/pyruvate, and improved NADH/NAD+ balance in heart and brain. Our study lays the groundwork for a class of injectable therapeutic enzymes that alleviate intracellular redox imbalances by directly targeting circulating redox-coupled metabolites.